As of 2025-07-13, the Intrinsic Value of Gemini Therapeutics Inc (GMTX) is - USD. This GMTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.35 USD, the upside of Gemini Therapeutics Inc is -100.00%.
Based on its market price of 1.35 USD and our intrinsic valuation, Gemini Therapeutics Inc (GMTX) is overvalued by 100.00%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | - - - | - | -100.00% |
| P/E | (14.57) - (20.40) | (15.02) | -1212.8% |
| DDM - Stable | (10.24) - (29.89) | (20.06) | -1586.2% |
| DDM - Multi | (6.66) - (15.26) | (9.29) | -788.3% |
| Market Cap (mil) | 58.49 |
| Beta | 1.10 |
| Outstanding shares (mil) | 43.33 |
| Enterprise Value (mil) | -319.11 |
| Market risk premium | 5.00% |
| Cost of Equity | 9.32% |
| Cost of Debt | 5.00% |
| WACC | 6.50% |